GELS vs EVO Stock Comparison

Gelteq and Evotec SE Prices as of Oct 26, 2026 Peers: Industry group
GELS Gelteq Ltd
$0.45 -18.2% 1M -63.7% 1Y
Market cap
$4.08M
P/E
–
Revenue (TTM)
—
Div. yield
–
Contract Manufacturing Healthcare
EVO Evotec SE
$1.52 -1.9% 1M -62.9% 1Y
Market cap
$555.82M
P/E
–
Revenue (TTM)
—
Div. yield
–
Contract Research Healthcare
3 wins

Head to Head

3 decided of 12

Evotec SE leads on 3 of the 12 questions below (Evotec SE 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGELSEVOLeader
Larger companyMarket capitalisation $4.08M $555.82M EVO
Cheaper on earningsLower P/E, profitable companies only — — –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — –
Faster revenue growthRevenue growth, trailing twelve months — — –
More profitableNet margin, trailing twelve months — — –
Better return on capitalReturn on invested capital — — –
Less leveragedLower net debt / EBITDA — — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -63.7% -62.9% EVO
Better 5-year returnAnnualised price return, 5 years — — –
Less volatileAnnualised volatility, 1 year 159.8% 58.0% EVO
Higher overall scoreMean of the five percentile scores vs peers — — –

Percentile Scorecard

GELSEVO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGELSEVO
Valuation – –
Growth – –
Profitability – –
Financial Health 67 #5 of 13 92 #2 of 13
Shareholder Returns – –
Overall – –
  • GELS ranked among 13 companies in Pharma Services
  • EVO ranked among 13 companies in Pharma Services

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGELSEVOSPY
1 month -18.2%-1.9% -0.8%
3 months -31.8%-20.8% +3.5%
6 months -35.3%-51.6% +7.0%
Year to date -43.8%-50.6% +12.2%
1 year -63.7%-62.9% +13.0%
3 years —-81.8% +86.3%
3 years, per year —-43.4% +23.1%

Risk

MeasureGELSEVOSPY
Volatility, 1Y 159.8%58.0% 12.7%
Downside volatility, 1Y 122.0%65.3% 12.7%
Beta vs S&P 500, 1Y 2.061.49 1.00
Return / volatility, 1Y -0.40-1.08 1.02
Max drawdown, 5Y -91.9%-94.6% -25.4%
From 52-week high -70.6%-63.4% -1.8%
52-week high $1.53$4.15 $779.14
52-week low $0.39$1.35 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGELSEVO
P/E now vs peer median —median 36.5x —median 36.5x
P/S now vs peer median —median 2.7x —median 2.7x
EV/EBITDA now vs peer median —median 37.7x —median 37.7x
P/FCF now vs peer median -6.8xmedian 20.7x —median 20.7x
P/B now vs peer median 0.5xmedian 2.9x 0.7xmedian 2.9x
PEG now vs peer median —median 2.04 —median 2.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGELSEVO
Cash & equivalents $6.26K $397.89M
Total debt $8.91M $1.96B
Shares (diluted) 9.27M –
Enterprise value $1.94M -$1.06B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGELSEVO
P/E – –
P/FCF -6.8x –
P/Operating cash flow – –
P/S – –
P/B 0.5x 0.7x
P/Tangible book -1.4x 0.7x
EV/EBITDA – –
EV/EBIT – –
EV/Revenue – –
EV/FCF – –
EV/Operating cash flow – –
PEG (3Y EPS CAGR) – –

Growth

14 metrics
MetricGELSEVO
Revenue growth (1Y) – –
Revenue CAGR (3Y) – –
Gross profit growth (1Y) – –
Gross profit CAGR (3Y) – –
Operating income growth (1Y) – –
Operating income CAGR (3Y) – –
Net income growth (1Y) – –
Net income CAGR (3Y) – –
EPS growth (1Y) – –
EPS CAGR (3Y) – –
Operating cash flow growth (1Y) – –
Operating cash flow CAGR (3Y) – –
Free cash flow growth (1Y) – –
Free cash flow CAGR (3Y) – –

Profitability

14 metrics
MetricGELSEVO
Gross margin – –
EBITDA margin – –
Operating margin – –
Pretax margin – –
Net margin – –
FCF margin – –
Operating cash flow margin – –
Return on equity – –
Return on assets – –
Return on invested capital – –
Return on capital employed – –
Asset turnover – –
Cash conversion (OCF / net income) – –
Stock comp / revenue – –

Financial Health

11 metrics
MetricGELSEVO
Debt / assets 0.1% 30.2%
Debt / equity 0.0x 0.7x
Net debt / EBITDA – –
Debt / FCF – –
Liabilities / assets 29.4% 57.7%
Equity / assets 70.6% 42.3%
Interest coverage – –
Current ratio 0.1x 2.3x
Quick ratio 0.1x 1.6x
Cash ratio 0.0x 1.2x
Altman Z-score – –

Shareholder Returns

7 metrics
MetricGELSEVO
Dividend yield – –
Net buyback yield – –
Shareholder yield – 0.0%
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGELSEVO
EPS, next fiscal year – $-0.72FY2026
Revenue, next fiscal year – $682.51MFY2026
Revenue growth, next FY – -26.0%FY2026
Revenue growth, the year after – +23.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGELSEVO
Held by institutions – 0.9%
Institutions holding – 35
Change in shares held, QoQ – -60.2%
Institutions buying – 18
Institutions selling – 7
Buyers to sellers – 2.57

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GELSEVO
GELS 1.00 0.09
EVO 0.09 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GELS and EVO?

Evotec SE (EVO) is the largest by market capitalisation: Gelteq (GELS) $4.08M, Evotec SE (EVO) $555.82M.

Which stock has performed better?

Over the past year Evotec SE (EVO) returned the most: Gelteq (GELS) -63.7%, Evotec SE (EVO) -62.9%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Evotec SE (EVO) has been the steadiest (Gelteq (GELS) 159.8%, Evotec SE (EVO) 58.0%). Volatility measures how widely the price swings, not the risk of the business.

Do GELS and EVO move together?

Their daily returns over the past year have a correlation of 0.09, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, GELS and EVO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Evotec SE (EVO) leads on 3. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.